Matching articles for "ezetimibe/simvastatin"
Issue 1565 · February 11, 2019
Lipid-Lowering Drugs

Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force have recently been published. See Table 1 for a brief summary of their recommendations.

Med Lett Drugs Ther. 2019 Feb 11; 61(1565):17-24
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force have recently been published. See Table 1 for a brief summary of their recommendations.
Issue 1565 · February 11, 2019
Expanded Table: Lipid-Lowering Drugs (online only)

View the Expanded Table: Lipid-Lowering Drugs

Med Lett Drugs Ther. 2019 Feb 11; 61(1565):e24-30
View the Expanded Table: Lipid-Lowering Drugs
Issue 1506 · October 24, 2016
Lipid-Lowering Drugs

Lipid-lowering drugs should be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels. HMG-CoA reductase inhibitors (statins) remain the drugs of choice for treatment of…

Med Lett Drugs Ther. 2016 Oct 24; 58(1506):133-40
Lipid-lowering drugs should be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels. HMG-CoA reductase inhibitors (statins) remain the drugs of choice for treatment of most patients who require lipid-lowering therapy.
Issue 1457 · December 8, 2014 Free
In Brief: Adding Ezetimibe to a Statin Improves Clinical Outcomes

Combining a statin with another drug that lowers low-density lipoprotein cholesterol (LDL-C), such as colesevelam (Welchol) , niacin ( Niaspan , and others), or ezetimibe (Zetia) , can reduce LDL-C levels more…

Med Lett Drugs Ther. 2014 Dec 8; 56(1457):126
Combining a statin with another drug that lowers low-density lipoprotein cholesterol (LDL-C), such as colesevelam (Welchol) , niacin ( Niaspan , and others), or ezetimibe (Zetia) , can reduce LDL-C levels more than a statin alone, but studies convincingly demonstrating that such combinations improve clinical outcomes have been lacking. The results of a long-term randomized, double-blind clinical trial (IMPROVE-IT) recently presented at the American Heart Association's Scientific Sessions 2014 indicate that addition of ezetimibe to simvastatin in high-risk patients reduces cardiovascular events. 1 IMPROVE-IT compared the efficacy of simvastatin 40 mg plus placebo with that of simvastatin 40 mg plus ezetimibe 10 mg (Vytorin) in preventing the primary endpoint, a composite of cardiovascular events (cardiovascular death, MI, hospital admission for unstable angina, coronary revascularization, or stroke) in patients with acute coronary syndrome and normal LDL-C levels (≤125 mg/dL; mean 95 mg/dL). After one year, mean LDL-C was reduced further with the addition of ezetimibe (to 53.2 vs. 69.9 mg/dL with simvastatin alone). After 7 years, 2742 events had occurred among the 9077 patients taking simvastatin plus placebo and 2572 among the 9067 taking simvastatin plus ezetimibe (event rate: 34.7% vs. 32.7%; p = 0.016). There was no significant difference between the 2 groups in noncardiovascular adverse events, including gallbladder-related events, myopathy, or cancer. C Cannon et al. IMProved Reduction of Outcomes: Vytorin Efficacy International Trial. Available at www.timi.org. Accessed November 21, 2014. Download complete U.S. English article
Issue 137 · January 1, 2014
Drugs for Lipids

HMG-CoA reductase inhibitors (statins) inhibit the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. The subsequent reduction in hepatic cholesterol leads to increased expression of LDL…

Treat Guidel Med Lett. 2014 Jan; 12(137):1-6
HMG-CoA reductase inhibitors (statins) inhibit the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. The subsequent reduction in hepatic cholesterol leads to increased expression of LDL receptors, which in turn increases uptake and clearance of LDL-C from the blood. Statins also lower very low-density lipoprotein cholesterol (VLDL-C) and triglycerides. Most statins increase high-density lipoprotein cholesterol (HDL-C), but only modestly.
Issue 1419 · June 24, 2013
Liptruzet: A Combination of Ezetimibe and Atorvastatin

The FDA has approved a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe and the HMG-CoA reductase inhibitor (statin) atorvastatin as Liptruzet (Merck) for treatment of hyperlipidemia.…

Med Lett Drugs Ther. 2013 Jun 24; 55(1419):49-50
The FDA has approved a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe and the HMG-CoA reductase inhibitor (statin) atorvastatin as Liptruzet (Merck) for treatment of hyperlipidemia. Ezetimibe is also available in a fixed-dose combination with simvastatin (Vytorin) .
Issue 1381 · January 9, 2012 Free
In Brief: Ezetimibe/Simvastatin (Vytorin) in Chronic Kidney Disease

An FDA advisory committee has voted in favor of approving ezetimibe/simvastatin ( Vytorin – Merck) for prevention of major cardiovascular events in patients with chronic kidney disease who are not on…

Med Lett Drugs Ther. 2012 Jan 9; 54(1381):4
An FDA advisory committee has voted in favor of approving ezetimibe/simvastatin ( Vytorin – Merck) for prevention of major cardiovascular events in patients with chronic kidney disease who are not on dialysis. The FDA itself is expected to make a decision on this potential new indication in the first quarter of 2012. The manufacturer’s application for this new indication was based on a double-blind, randomized trial (SHARP) that compared the combination of ezetimibe 10 mg and simvastatin 20 mg with placebo in 9270 patients with chronic kidney disease who did not have a history of myocardial infarction or coronary revascularization. 1 About one-third of patients were already on hemodialysis at the start of the trial. Over a median of 4.9 years, a major atherosclerotic event (the primary endpoint) occurred in 526 patients (11.3%) taking the active drugs and in 619 (13.4%) taking placebo. Myopathy occurred in 9 patients (0.2%) randomized to ezetimibe/simvastatin and in 5 (0.1%) of those in the placebo group, not a significant difference. Whether simvastatin alone, which would cost much less, would similarly improve outcomes in such patients remains to be determined. The FDA advisory committee did not recommend approval of Vytorin for patients who were on hemodialysis. 2 Previous trials with a statin alone in patients with end-stage renal disease on hemodialysis failed to show significant benefits in clinical outcomes. 3,4 1. C Baigent et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181. 2. S Sutter. Merck’s bid for Vytorin CV benefit claim muddled by earlier statin failures in dialysis patients. The Pink Sheet, November 7, 2011. 3. C Wanner et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238. 4. BC Fellström et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.N Engl J Med 2009; 360:1395. Download U.S. English
Issue 1370 · August 8, 2011
New Simvastatin Dosing Recommendations

The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months…

Med Lett Drugs Ther. 2011 Aug 8; 53(1370):61-2
The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months or more without evidence of myopathy and new recommendations for use of simvastatin with other drugs. Simvastatin is available alone ( Zocor , and others) and in combination with ezetimibe (Vytorin) and with niacin (Simcor) .
Issue 103 · March 1, 2011
Drugs for Lipids

Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. Lipid-regulating drugs must be taken…

Treat Guidel Med Lett. 2011 Mar; 9(103):13-20
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels in 2-3 weeks.